Science marketing & communication 🧬 scaling up your content production 🧬 2-time founder (1 exit, 1 active)
With #JPM2024 behind us, #biotech fundraising seems to be returning to a more regular pace. ✅ Here's what our tracker found this week: 🇺🇸 Dyne Therapeutics | $345.1 million public offering | muscle disease therapies | clinical in myotonic dystrophy type 1 🇺🇸 Praxis Precision Medicines, Inc. | $150 million public offering | precision medicine | clinical in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy | Read more 🇺🇸 Myrobalan Therapeutics | $24 million series A | CNS disease therapies | IND-enabling in multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis 🇩🇪 DISCO Pharmaceuticals GmbH | EUR 20 million ($21.75 million) seed | drug discovery | map of small cell lung cancer surfaceome completed 🇨🇭 STALICLA | $17.4 million series B | neurodevelopmental disorder-specific precision medicine platform | phase 1b in autism spectrum disorder 🇫🇮 DelSiTech Ltd | €10 million ($10.88 million) | drug delivery | clinical in chronic hepatitis B 🇺🇸 Cyrano Therapeutics | $9 million series B | phase 2 in post-viral smell loss 🇨🇦 XORTX Therapeutics Inc. | $2 million public offering | orphan disease indications | phase 2 in polycystic kidney disease 📌 Subscribe to Labiotech.eu to receive all our biotech updates.
CEO BioStock — Connecting Innovation & Capital
7moHi Joachim, just curious: do you use an AI tool to track these transactions? (Seeing as you wrote ”…what our tracker found”, makes it sound like a 🤖 helper 😉) Best/Jonas